Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights
Evommune, Inc. (EVMN) Discusses Scientific Rationale and Pipeline Expansion for MRGPRX2 Antagonist in Migraine Prevention Transcript
Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine
Capricorn Fund Managers Ltd Acquires Shares of 60,000 Evommune, Inc. $EVMN
Evommune, Inc. (NYSE:EVMN) Receives Average Rating of “Moderate Buy” from Analysts
1 Under‑the‑Radar Biotech to Buy for Potential 10X Growth in the Next Decade
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
Evommune, Inc. (NYSE:EVMN) Receives Average Recommendation of “Moderate Buy” from Brokerages
Evommune Announces $125 Million Private Placement
Evommune Stock Cools Off After Big Rally On Successful Eczema Trial
Evommune's Stock Surges On Strong Results For New Eczema Drug
Evommune Nearly Doubles — Has Dupixent Met Its Match In Eczema?
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis
Evommune, Inc. (NYSE:EVMN) Given Consensus Recommendation of “Buy” by Analysts
High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026
Evommune (NYSE:EVMN) Director Robert Lorne Hopfner Purchases 1,000 Shares
Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update
Evommune Announces Pricing of its Initial Public Offering
Evommune Announces Commencement of Initial Public Offering